NDAORALCAPSULE
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JUXTAPID (lomitapide mesylate) is an oral small-molecule microsomal triglyceride transfer protein (MTP) inhibitor approved in 2012 for homozygous familial hypercholesterolemia (HoFH), a rare genetic lipid disorder. It reduces apolipoprotein B-containing lipoprotein production in the liver, effectively lowering LDL cholesterol levels in patients with severely elevated baseline lipids.
$0.009BPart D
Peak14.7 years to LOEStable niche product with modest spending and claims volume typical of rare disease indicated drugs; team size likely small and specialized.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on JUXTAPID offers deep specialization in rare-disease commercialization with direct patient engagement and high-touch managed care strategy; however, zero current job openings and minimal team size limit entry points. This is a niche, stable platform ideal for rare-disease career development but not suitable for broad pharma exposure or rapid mobility.
Rare Disease Specialist
Worked on JUXTAPID at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.